Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $34.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 463.27% year-over-year to $34.1 million in Q1 2026; TTM through Mar 2026 was $34.1 million, a 463.27% increase from a year earlier, with the FY2025 full-year figure at $43.9 million, up 612.64% from the prior year.
• Other Non-Current Liabilities fell to $34.1 million in Q1 2026 per LCTX's latest filing, from $43.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $45.2 million in Q3 2025 and bottomed at $1000.0 in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $3.0 million (2022), against an average of $12.9 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 93.33% in 2022 and jumped 612.64% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $2000.0 in 2022, then sank by 50.0% to $1000.0 in 2023, then surged by 616000.0% to $6.2 million in 2024, then soared by 612.64% to $43.9 million in 2025, then dropped by 22.24% to $34.1 million in 2026.
• Per Business Quant, the three latest LCTX Other Non-Current Liabilities figures stand at $34.1 million (Q1 2026), $43.9 million (Q4 2025), and $45.2 million (Q3 2025).